naratriptan has been researched along with Migraine with Aura in 1 studies
naratriptan: structure given in first source
Migraine with Aura: A subtype of migraine disorder, characterized by recurrent attacks of reversible neurological symptoms (aura) that precede or accompany the headache. Aura may include a combination of sensory disturbances, such as blurred VISION; HALLUCINATIONS; VERTIGO; NUMBNESS; and difficulty in concentrating and speaking. Aura is usually followed by features of the COMMON MIGRAINE, such as PHOTOPHOBIA; PHONOPHOBIA; and NAUSEA. (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Luciani, R | 1 |
| Carter, D | 1 |
| Mannix, L | 1 |
| Hemphill, M | 1 |
| Diamond, M | 1 |
| Cady, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Single-Blind Pilot Study to Compare the Efficacy and Cost-Effectiveness of Frovatriptan vs. Topiramate for the Prevention of Migraine[NCT00846495] | Phase 4 | 55 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Includes Adverse Events at or above 5% frequency per group. (NCT00846495)
Timeframe: Treatment Months 1 and 2
| Intervention | Adverse Events (Number) |
|---|---|
| Topiramate | 26 |
| Frovatriptan | 11 |
Measure the change in number of headache days between participants using frovatriptan in a preemptive treatment paradigm vs. daily topiramate to prevent migraine (NCT00846495)
Timeframe: Treatment Month 2
| Intervention | Headache Days (Mean) |
|---|---|
| Topiramate | 4.75 |
| Frovatriptan | 2.79 |
Compare number of migraine attacks reported by participants using frovatriptan in a preemptive treatment paradigm vs. daily topiramate during Treatment Period Month 2 (NCT00846495)
Timeframe: Treatment Month 2
| Intervention | Migraine attacks (Mean) |
|---|---|
| Topiramate | 1.35 |
| Frovatriptan | 2.12 |
Average cost of study medication taken by each subject. Measured in dollars. (NCT00846495)
Timeframe: Treatment Months 1 and 2
| Intervention | Dollars (US) (Mean) | ||
|---|---|---|---|
| Preventive Medication Taken | Rescue Medication Taken | All Study Medication Taken | |
| Frovatriptan | 101.41 | 59.94 | 161.35 |
| Topiramate | 343.56 | 38.33 | 381.89 |
Measure the change in number of headache days reported by participants during each treatment month following initiation of treatment with study medication (NCT00846495)
Timeframe: 2 Months
| Intervention | Headache Days (Mean) | |
|---|---|---|
| Treatment Month 1 | Treatment Month 2 | |
| Frovatriptan | 3.96 | 3.42 |
| Topiramate | 4.20 | 1.75 |
"Participant satisfaction is measured by the Patient Perception of Migraine Questionnaire (PPMQ). Questions were categorized within 6 dimensions: Efficacy, Functionality, Ease of Use, Cost, Bothersomeness of Side Effects, and Total Score. Scores range from 0 to 100. Higher scores represent better satisfaction.~Participants completed the PPMQ 24 hours following each first dose of frovatriptan." (NCT00846495)
Timeframe: Treatment Month 2
| Intervention | Score on a Scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Efficacy | Functionality | Ease of Use | Cost | Bothersomeness of Side Effects | Total Score | |
| Frovatriptan | 75.1977 | 76.3648 | 92.6989 | 59.0886 | 95.5398 | 81.1417 |
| Topiramate | 76.7857 | 77.8214 | 91.6607 | 81.2536 | 95.1786 | 82.0925 |
Compare number of participants with greater than 50% reduction in migraine attacks and headache days from Baseline to Treatment Months 1 and 2 (NCT00846495)
Timeframe: 2 Months
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Migraine Attacks Treatment Month 1 | Headache Days Treatment Month 1 | Migraine Attacks Treatment Month 2 | Headache Days Treatment Month 2 | |
| Frovatriptan | 13 | 9 | 15 | 13 |
| Topiramate | 11 | 7 | 15 | 16 |
Quality of Life is measured by the Migraine Specific Quality of Life Questionnaire (MSQ), which includes 3 dimensions: Role Function Restrictive (degree to which performance of daily activities is limited), Role Function Preventive (degree to which performance of daily activities is interrupted), and Emotional Function (frustration and helplessness due to migraine). Scores range from 0 to 100. For each dimension, a higher score indicates a better health status. Participants completed the MSQ at Randomization, and after Treatment Months 1 and 2. (NCT00846495)
Timeframe: Randomization, End of Treatment Month 1, End of Treatment Month 2
| Intervention | Score on a Scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Role Function Restrictive - Baseline | Role Function Restrictive - Treatment Month 1 | Role Function Restrictive - Treatment Month 2 | Role Function Preventive - Baseline | Role Function Preventive - Treatment Month 1 | Role Function Preventive - Treatment Month 2 | Emotional Function - Baseline | Emotional Function - Treatment Month 1 | Emotional Function - Treatment Month 2 | |
| Frovatriptan | 59.88 | 66.48 | 71.84 | 77.50 | 79.25 | 84.96 | 64.71 | 73.18 | 75.10 |
| Topiramate | 56.00 | 80.29 | 86.64 | 77.75 | 85.25 | 93.95 | 60.67 | 80.00 | 91.46 |
1 other study available for naratriptan and Migraine with Aura
| Article | Year |
|---|---|
Prevention of migraine during prodrome with naratriptan.
Topics: Adult; Female; Humans; Indoles; Male; Middle Aged; Migraine with Aura; Pilot Projects; Piperidines; | 2000 |